Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-14. (Canceled)

Claim 15. (Withdrawn) A method for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure which method comprises administering a therapeutically effective amount of a solid oral dosage form according to Claim 1 to a patient in need thereof.

Claim 16. (Withdrawn) A method for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure which method comprises administering a therapeutically effective amount of a solid oral dosage form according to Claim 12 to a patient in need thereof.

Claim 17. (Withdrawn) Use of a solid oral dosage form according to Claim 1 for the manufacture of a medicament for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure.

Claim 18. (Withdrawn) Use of a solid oral dosage form according to Claim 12 for the manufacture of a medicament for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure.

Claim 19. (Withdrawn) A process for the manufacture of a solid oral dosage form according to Claim 12 comprising:

1) mixing the active ingredient and additives and granulating said components with a granulation liquid;
2) drying a resulting granulate;
3) mixing the dried granulate with outer phase excipients;
4) compressing a resulting mixture to form a solid oral dosage as a core tablet; and

5) optionally coating a resulting core tablet to give a film-coated tablet.

Claim 20. (Withdrawn) A process according to Claim 19, wherein the additives in step (1) are selected from a filler, a disintegrant and a binder; and the outer phase excipients in step (3) are selected from a filler, a disintegrant, a lubricant and a glidant.

Claim 21. (Currently Amended) A solid oral dosage form comprising a therapeutically effective amount of aliskiren, or a pharmaceutically acceptable salt thereof, in an amount of more than 46% by weight based on the total weight of the oral dosage form, wherein the oral dosage form is in the form of a tablet and comprises a) an inner phase which is comprising aliskiren, or a pharmaceutically acceptable salt thereof, a filler, a binder, and a disintegrant, and b) an outer phase which is comprising a disintegrant, a filler, a glider, and a lubricant~~is not obtainable by wet granulation with excipients using water and/or an aqueous binder solution~~.

Claim 22. (Currently Amended) The solid oral dosage form according to Claim 21, wherein the tablet ~~is a film-coated tablet~~further comprises a film coat wherein said film coat comprises a filmcoating material selected from hydroxypropyl methyl cellulose, polyethylene glycols, polyvinylpyrrolidones, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohol, and sugar.

Claim 23. (Withdrawn) The solid oral dosage form according to Claim 21, wherein the tablet is chosen from a tablet in the form of multiparticulates, multiparticulate pellets, multiparticulate minitablets, wax matrix systems, polymer matrix tablets, polymer coated tablets, oral osmotic systems, coated tablets, matrix tablets, press-coated tablets, and multilayer tablets.

Claim 24. (Canceled)

Claim 25. (Canceled)

Claim 26. (Previously Presented) A solid oral dosage form according to Claim 21, wherein the active ingredient is present in an amount of more than 48% by weight.

Claim 27. (Previously Presented) A solid oral dosage form according to Claim 21, wherein the active ingredient is present in an amount ranging from 46 to 60% by weight.

Claim 28. (Currently Amended) A solid oral dosage form according to Claim 21~~7~~, wherein the active ingredient consists entirely of aliskiren, or a pharmaceutically acceptable salt thereof, and is present in an amount ranging from about 75 to about 600 mg of the free base per unit dosage form.

Claim 29. (Currently Amended) A solid oral dosage form according to Claim 28~~1~~, wherein the active ingredient consists entirely of aliskiren, or a pharmaceutically acceptable salt thereof, and

is present in an amount ranging from about 75 to about 300 mg of the free base per unit dosage form.

Claim 30. (Withdrawn) A solid oral dosage form according to Claim 29, wherein aliskiren is in the form of a hemi-fumarate thereof, and is present in an amount of about 83 mg per unit dosage form.

Claim 31. (Withdrawn) A solid oral dosage form according to Claim 29, wherein aliskiren is in the form of a hemi-fumarate thereof, and is present in an amount of about 166 mg per unit dosage form.

Claim 32. (Currently Amended) A solid oral dosage form according to Claim ~~29~~8, wherein aliskiren is in the form of a hemi-fumarate thereof, and is present in an amount of about 332 mg per unit dosage form.

Claim 33. (Currently Amended) A solid oral dosage form according to ~~any of~~ Claims ~~29-31~~, wherein the dosage form further comprises a filler.

Claim 34. (Previously Presented) A solid oral dosage form according to Claim 33, wherein the filler is microcrystalline cellulose.

Claim 35. (Currently Amended) A solid oral dosage form according to Claim ~~33~~21, wherein the dosage form further comprises a disintegrant.

Claim 36. (Currently Amended) A solid oral dosage form according to Claim ~~35~~21, wherein the dosage form further comprises a lubricant.

Claim 37. (Currently Amended) A solid oral dosage form according to Claim ~~36~~21, wherein the dosage form further comprises a glidant.

Claim 38. (Currently Amended) A solid oral dosage form according to Claim ~~37~~21, wherein the dosage form further comprises a binder.

Claim 39. (Previously Presented) A solid oral dosage form according to Claim 21 for use in the manufacture of a medicament for the treatment of hypertension.

Claim 40. (New) A solid oral dosage form according to Claim 21, wherein the active ingredient is present in an amount of more than 46% up to 56% by weight.

Claim 41. (New) A solid oral dosage form according to Claim 33, wherein the filler is selected from starches, hydroxyproply cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, microcrystalline cellulose, confectioner's sugar, compressible sugar, dextrates, dextrin, dextrose, lactose, mannitol, powdered cellulose, sorbitol, sucrose, and talc.

Claim 42. (New) A solid oral dosage form according to Claim 35, wherein the disintegrant is selected from carboxymethylcellulose calcium, carboxymethylcellulose sodium, crosslinked polyvinylpyrrolidones, alginic acid, sodium alginate, guar gum, crosslinked carboxymethylcellulose, and carboxymethylstarch-Na.

Claim 43. (New) A solid oral dosage form according to Claim 42, wherein the disintegrant is crosslinked polyvinylpyrrolidone.

Claim 44. (New) A solid oral dosage form according to Claim 36, wherein the lubricant is selected from Mg stearate, aluminum or Ca stearate, polyethylene glycols 4000 to 8000, talc, hydrogenated castor oil, stearic acid and salts thereof, glycerol esters, Na-stearylfumarate, and hydrogenated cotton seed oil.

Claim 45. (New) A solid oral dosage form according to Claim 44, wherein the lubricant is Mg stearate.

Claim 46. (New) A solid oral dosage form according to Claim 37, wherein the glidant is selected from colloidal silica, magnesium trisilicate, powdered cellulose, starch, talc, tribasic calcium phosphate, and silicified microcrystalline cellulose.

Claim 47. (New) A solid oral dosage form according to Claim 46, wherein the glidant is colloidal silica.

Claim 48. (New) A solid oral dosage form according to Claim 38, wherein the binder is selected from polyvinylpyrrolidones, hydroxypropyl methyl cellulose, and polyethylene glycols.

Claim 49. (New) A solid oral dosage form according to Claim 48, wherein the binder is polyvinylpyrrolidone.

Claim 50. (New) A solid oral dosage form according to Claim 22, wherein the filmcoating material is hydroxypropyl methyl cellulose.

Claim 51. (New) A solid oral dosage form according to Claim 22 or 50, wherein the film coat further comprises additives selected from pigments, dies, titanium dioxide, iron oxides, talc, and polyethylene glycols 3350, 4000, 6000 and 8000.

Claim 52. (New) A solid oral dosage form according to Claim 22, wherein the film coat comprises hydroxypropyl methyl cellulose, iron oxide pigments, titanium dioxide, polyethylene glycol, and talc.